Open Access Repository

The VEGF treatment of AMD switch study (The vTAS study)

Downloads

Downloads per month over past year

Curry, B, Bylsma, G, Hewitt, AW ORCID: 0000-0002-5123-5999 and Verma, N 2017 , 'The VEGF treatment of AMD switch study (The vTAS study)' , Asia-Pacific Journal of Ophthalmology, vol. 6, no. 6 , pp. 481-487 , doi: 10.22608/APO.2017364.

[img] PDF
126257 Journal ...pdf | Request a copy
Full text restricted

Abstract

Purpose: To evaluate the effect of aflibercept on anatomic and visual outcomes in patients with choroidal neovascularization (CNV) previously treated with intravitreal ranibizumab with persistent fluid on optical coherence tomography (OCT).Design: Prospective, open-label study.Methods: Eighteen patients (19 eyes) with CNV being treated with monthly ranibizumab, with persistent fluid on OCT, were switched to intravitreal aflibercept injections at intervals of up to 8 weeks. The primary outcome was the proportion of patients maintaining vision [Results: Forty-eight weeks after switching to aflibercept, 16/19 eyes had maintained VA. There was a median increase in vision of 5 letters [interquartile range (IQR): 0, 15; P = 0.06)] and median CMT was reduced from 313 µm (IQR: 214, 334) to 258 µm (IQR: 200, 299; P = 0.02). After stratification by fluid location the reduction in CMT was statistically significant for eyes with intraretinal fluid (IRF) at baseline [median change, -25 µm (IQR: -14, -64); P = 0.01]. Macular volume within 6 mm of the fovea (CMTVol) was significantly reduced in eyes with subretinal fluid (SRF) [-0.20 mm³ (IQR: -1.45, -0.05); P = 0.03].Conclusions: In this small cohort of eyes, switching to aflibercept seemed beneficial. The majority maintained or improved vision and eyes with IRF or SRF had significant reductions in macular edema. However, visual improvement was not always indicative of anatomical improvement.

Item Type: Article
Authors/Creators:Curry, B and Bylsma, G and Hewitt, AW and Verma, N
Keywords: aflibercept, neovascular age-related macular degeneration, ranibizumab
Journal or Publication Title: Asia-Pacific Journal of Ophthalmology
Publisher: Singapore National Eye Centre
ISSN: 0129-1653
DOI / ID Number: 10.22608/APO.2017364
Copyright Information:

© 2017 Asia-Pacific Academy of Ophthalmology. Unauthorized reproduction of this article is prohibited.

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP